Specialty Pharma Journal Specialty, Precision & Technology
South Korea’s Samsung Bioepis Co., Ltd. recently announced that it has submitted a marketing authorization application (MAA) for SB2, its Remicade (infliximab) biosimilar candidate to European health regulators. The company said that it has submitted the MAA to the European Medicines Agency (EMA). The MAA for SB2 is the second …
Tag Archives: biogen idec
March, 2015
-
2 March
Biogen and Sobi’s Hemophilia B Drug Succeeds in Phase III Trial in Children
Biogen Idec and Swedish Orphan Biovitrum AB (Sobi) recently announced positive results from its late-stage hemophilia B study. The companies announced top-line results of the Kids B-LONG Phase III clinical study that evaluated the safety, efficacy and pharmacokinetics of Alprolix [Coagulation Factor IX (Recombinant), Fc Fusion Protein] in children under …
January, 2015
-
29 January
Biogen Partners to Develop Gene Therapies for Hemophilia
Biogen Idec is teaming up with Fondazione Telethon and Ospedale San Raffaele to develop gene therapies for hemophilia A and B. The worldwide collaboration will combine San Raffaele-Telethon Institute for Gene Therapy’s (TIGET) extensive expertise in creating new gene therapy strategies and developing them from bench to bedside with Biogen’s …
-
9 January
Biogen’s anti-LINGO-1 Demonstrates Mixed Results in Study
Biogen Idec said that its experimental multiple sclerosis (MS) drug showed signs that it could help repair nerve damage in patients’ eyes. The company announced top-line results from the Phase II acute optic neuritis (AON) RENEW trial. According to Biogen, treatment with its anti-LINGO-1 showed evidence of biological repair of …